{"id":"W4379981083","doi":"10.1002/hon.3163_t04","title":"MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Pharmacyclics; Seagen; BeiGene; Celgene; Gilead Sciences","keywords":"Obinutuzumab; Medicine; Lenalidomide; Rituximab; Ibrutinib; Internal medicine; Idelalisib; Oncology; Bruton's tyrosine kinase; Follicular lymphoma; Salvage therapy; Chronic lymphocytic leukemia; Lymphoma; Chemotherapy; Leukemia; Multiple myeloma; Tyrosine kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001009327,0.001027791,0.001474832,0.0003922057,0.0004703767,0.001178659,0.001106741,0.001015699,0.007732849],"category_scores_gemma":[0.0008124285,0.0003934782,0.001167997,0.0003415374,0.0008386464,0.0008843876,0.0005318969,0.002760458,0.001297809],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001180802,"about_ca_system_score_gemma":0.001362726,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001613339,"about_ca_topic_score_gemma":0.007608562,"domain_scores_codex":[0.9996259,0.0001923858,0.00001175595,0.0000540649,0.00003638444,0.00007942745],"domain_scores_gemma":[0.9996799,0.00005976139,0.00006123941,0.00002122684,0.00002148669,0.0001564291],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8402079,0.01158088,0.002881867,0.002308222,0.002009506,0.0001987752,0.0004406976,0.002120971,0.01661001,0.001267635,0.01425544,0.1061181],"study_design_scores_gemma":[0.9114746,0.07000343,0.006781679,0.0001700538,0.0007060949,0.0002536937,0.00009535968,0.00150375,0.0009085111,0.0006213955,0.007428656,0.00005284086],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9691047,0.009959421,0.0006274287,0.002361543,0.0005541148,0.002948808,0.003131152,0.0003929851,0.01092002],"genre_scores_gemma":[0.9806285,0.003603227,0.001630922,0.002145836,0.0002457543,0.002539849,0.003174067,0.00005929269,0.005972617],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007732849,"threshold_uncertainty_score":0.02586889,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06003095277318925,"score_gpt":0.3721584572127411,"score_spread":0.3121275044395518,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}